Reversal of epigenetic aging and immunosenescent trends in humans (TRIIM trial)

Researchers gave nine healthy men aged 51 to 65 a daily combination of growth hormone and two existing medicines for one year. They checked the thymus, an organ that helps train infection-fighting immune cells, along with blood tests. They also measured epigenetic age, an estimate based on chemical marks on DNA that can change with aging. The men’s epigenetic age appeared to decrease by about 2.5 years on average, but the study had no untreated comparison group.

What this means for you: This was a tiny early study, so it does not show that the treatment slows aging or improves health. Do not buy growth hormone or these medicines for anti-aging use based on this result, especially because they can have serious side effects.